Search tips
Search criteria 


Logo of bmmLink to Publisher's site
Biomark Med. 2016 March; 10(3): 265–300.
Published online 2016 February 29. doi:  10.2217/bmm.16.1
PMCID: PMC5493965

Sleep apnea in total joint arthroplasty patients and the role for cardiac biomarkers for risk stratification: an exploration of feasibility


Obstructive sleep apnea (OSA) is highly prevalent in patients undergoing total joint arthroplasty (TJA) and is a major risk factor for postoperative cardiovascular complications and death. Recognizing this, the American Society of Anesthesiologists urges clinicians to implement special considerations in the perioperative care of OSA patients. However, as the volume of patients presenting for TJA increases, resources to implement these recommendations are limited. This necessitates mechanisms to efficiently risk stratify patients having OSA who may be susceptible to post-TJA cardiovascular complications. We explore the role of perioperative measurement of cardiac troponins (cTns) and brain natriuretic peptides (BNPs) in helping determine which OSA patients are at increased risk for post-TJA cardiovascular-related morbidity.

Keywords: : brain natriuretic peptide, obstructive sleep apnea, postoperative complications, total joint arthroplasty, troponin

Over 1 million total hip and knee joint arthroplasty (total joint arthroplasty [TJA]) surgeries were performed in the USA in 2012, with costs exceeding $25 billion [1,2]. Projection models predict a profound increase in the number of TJAs that will be performed by 2030, estimating a twofold and sixfold increase in total hip and knee arthroplasties, respectively [2]. The average patient presenting for TJA is older and obese [2]. Importantly, this demographic is also at increased risk for the common medical disorder of obstructive sleep apnea (OSA) [3–7]. Recent studies have identified the growing role of OSA as a major risk factor for adverse post-TJA cardiovascular complications, including death [8–16].

OSA is defined by recurring episodes of airway collapse during sleep, which terminate in a burst of sympathetic activity and a resulting arousal from sleep [17]. These events result in cyclic, intermittent hypoxemia and sleep fragmentation, that lead to daytime sleepiness, multi-system physiologic perturbations and a host of adverse clinical conditions, that most commonly include cardiovascular complications [17–20]. Importantly, routine post-TJA clinical conditions (including noise [leading to sleep fragmentation], use of narcotics for pain control and supine positioning) exacerbate OSA symptoms and confer greater risk for post-TJA cardiovascular complications [9,10]. However, there is little information available that can be used to stratify which patients with OSA are especially at risk for post-TJA cardiovascular complications.

Given the expected increase in patients undergoing TJA, information that can be used for accurate and efficient cardiovascular-related risk stratification will be critical for effective post-TJA management of a patient with OSA. In this regard, the blood biomarkers cardiac troponins (cTns [cTnT or cTnI]) and brain natriuretic peptides (BNPs [BNP or N-terminal proBNP]) have shown promise for predicting risk of adverse cardiovascular-related 30-day morbidity or mortality in patients undergoing noncardiac surgery [21–47], TJA [48–58,59] and to a certain degree in OSA patients [60–73]. While these biomarkers have been studied in surgical patients and OSA patients, none of these studies directly evaluated the perioperative patient with OSA undergoing noncardiac surgery or TJA.

In this review, we evaluate the feasibility of using cTns and BNPs to risk stratify patients with OSA for cardiovascular complications post-TJA. We conclude that there is a logical link to be made in utilizing cTns and BNPs for predicting risk of cardiovascular-related adverse events in OSA patients undergoing TJA. However, given the lack of studies directly evaluating the populations of interest, more research is needed.

Literature search

A literature search was conducted using the PubMed, Embase and Scopus electronic databases, and references of articles, limited to human studies, English language and primarily elective surgeries conducted within the past 10 years. Our findings are presented chronologically (see Tables 2–7), as more recent assays have been found to be more precise and sensitive, reducing S/N in sensing the biomarker within the assay [74]. Our search strategy included MeSH and exploratory keywords including ‘troponin’, ‘brain natriuretic peptide’, ‘perioperative or postoperative complication’, ‘noncardiac’ or ‘non-cardiac’ ‘surgery’, ‘total hip’ or ‘knee’ ‘joint arthroplasty’ and ‘obstructive sleep apnea’. Our review excluded studies evaluating cTns and BNPs in cardiac surgery, as levels of cTns and BNPs are increased with cardiac instrumentation [75].

Total hip & knee joint arthroplasty (TJA)

Current trends show a growing prevalence in obesity [79] and an aging population [80], both of which increase the risk of joint disease, and cardiovascular disease [2]. Indeed, the group of patients undergoing TJA is unique as they typically have increased age, higher obesity levels and are also more likely to have pre-existing cardiovascular disease [2]. These trends of increasingly prevalent risk factors for TJA provide strong evidence that support projection models by the Task Force for Orthopedic Surgeons that the frequency of TJA procedures will continue to increase exponentially over the next decade [2]. The surgical procedure for TJA involves precise incisions through tissue of either the knee or hip, removal of eroded cartilage and bone, drilling into bone and compression of an artificial prosthesis into native bone structure [81,82]. Recovery in the immediate postoperative period requires increased pain control, periods of immobilization in the supine position and/or periods of limited or passive range of motion [81,82]. The most common post-TJA cardiovascular complications include pulmonary embolism (PE) and acute myocardial ischemia or myocardial infarction (MI) [1,83]. Patients undergoing major orthopedic procedures such as TJA carry a moderate risk (1–5%) of developing postoperative cardiac complications [84,85]. However, pre-existing cardiovascular co-morbidities in the older and obese patient presenting for TJA contributes to increased postoperative cardiac events that further complicate recovery [2]. Importantly, the existence of OSA in the TJA demographic further potentiates the manifestation and incidence of adverse postoperative cardiovascular complications [8–16].

Obstructive sleep apnea

The strongest risk factor for OSA is obesity [3–5,7]. Other major risk factors include advanced age [5], male gender and postmenopausal status in women [86]. Data from 2013, estimate that 34% of middle-aged men and 17% of middle-aged women suffer from at least mild OSA, and 13 and 6%, respectively, suffer from moderate-to-severe disease [5]. These estimates represent a clear increase in prevalence compared with the previous decade, reflecting the rising obesity levels in the population [5]. In-laboratory polysomnography (PSG) is the gold standard diagnostic tool for OSA, however, an unattended portable home sleep testing (HST) is accepted as a less expensive method of diagnosis for patients with a high pretest probability of OSA [87]. The primary measure of OSA severity is the apnea-hypopnea index (AHI) [87], the average number of apneas and/or hypopneas per hour of sleep (based on PSG) or recording time (when using HST). The AHI can be used to define disease severity as normal (AHI<5), mild (AHI≥5 and <15); moderate (AHI≥15 and ≤30) or severe (AHI>30) [87]. The main treatment for OSA is positive airway pressure (PAP), which works as a pneumatic splint to maintain airway patency, reduce arousals and restore oxygenation [87].

OSA has been shown to contribute to a wide variety of cardiovascular manifestations (see Figure 1), including coronary ischemia [18,66], myocardial infarction [18,66], arrhythmias [19,88], heart failure [89], hypertension [90], venous thromboembolism [91–94] and stroke [95]. Complex pathophysiological mechanisms, some that remain unclear, contribute toward the pathogenesis of cardiovascular events among OSA patients. These include the development of severe negative intrathoracic pressure as a result of arduous respiratory efforts to overcome upper airway collapse, sympathetic activation during episodes of apnea, sleep fragmentation and increased rapid eye movement (REM) activity, intermittent hypoxemic stress, dysregulation in neurohumoral, carotid chemoreflex (augmented) and baroreflex (reduced) function, inflammation, endothelial dysfunction, metabolic dysregulation and thrombosis [17,20,96,97]. Over time, recurrent swings in negative intrathoracic pressure can lead to increased cardiac preload and left ventricular afterload, increased cardiac work load, ventricular wall stress, unmet myocardial oxygen demand in the presence of alveolar hypoxia and hypercapnia and ultimately myocardial stress, ischemia, injury or infarction [17,20,97]. Furthermore, increased cardiac work, altered cardiac stretch and cardiac mechanoreceptors, systemic hypoxemia, respiratory acidosis (from carbon dioxide retention) and sympathetic hyperactivity contribute to dysregulated cardiac automaticity and arrhythmias [17,20,97]. Increased sympathetic activity and REM activity also contribute to blood pressure surges, fluctuating vagal tone, decreased heart rate variability, disruption in cardiac automaticity and arrhythmias [17,65,96].

Figure 1.
Common postoperative complications in the patient with obstructive sleep apnea following total joint arthroplasty.

In addition to these pathophysiological mechanisms, cycles of intermittent hypoxia that occur in OSA activate vascular inflammatory pathways, and produce pro-inflammatory cytokines, reactive oxygen species and increased expression of adhesion molecules, which in turn contribute to endothelial dysfunction and atherosclerosis [17,96]. Increased levels of pro-coagulant factors (such as plasminoger-activator inhibitor type-1, fibrinogen or platelet activity and aggregation) [91,93,94] are linked to OSA severity and circadian variation contributing to early morning fibrinolytic activity [98,99] and cardiovascular events [100–104]. These same mechanisms associated with cardiac myocyte stress have been shown to be triggers for the release of cTns and BNPs [75,105], making these biomarkers a potential indicator for OSA-related cardiovascular risk.

TJA, OSA & adverse outcomes

The co-existence of common clinical conditions in the perioperative treatment of TJA patients (see Box 1) further potentiates the effects of OSA [12,13,106–119]. The use of general anesthetics, opioid pain control, benzodiazepines and supine patient positioning during and post-TJA all act to promote and prolong airway closure, worsening desaturation and increasing the frequency of sympathetic bursts that accompany the termination of sleep-disordered breathing events [8–11,14,83,120–124]. Additionally, standard patient care activities, noise, light, pain and surgical stress [125] not only disrupt sleep architecture, but also increase sympathetic activity [10] and inflammation [125]. Taken together, this may render patients with OSA who undergo TJA at even greater risk for postoperative cardiovascular complications compared with patients without OSA. Several studies have found that most postoperative complications typically occurred within the first 24–72 h of surgery, a period of time during which disruptions from these clinical conditions are more prominent [10,107,108,111,114,117,119].

Box 1.

Clinical conditions that exacerbate pathophysiology and symptoms in postoperative patients with obstructive sleep apnea.

Use of general anesthetics, opioids, hypnotics, benzodiazepines [10,13,107,112,114,115,117,119,126]

  • Increased critical airway pressure.
  • Increased incidence of pharyngeal collapse from reduction in genioglossus muscle activity.
  • Decreased hypoxemic and hypercapnia ventilatory response from effects on peripheral chemoreflex loop and peripheral chemoreceptors.
  • Impaired arousal response.
  • Decreased minute ventilation.

Patient positioning [126]

  • Increased use of supine positioning following TJA.

Exposure to environmental factors (patient care activities, noise, light, pain, surgical stress) [10,97,119,125]

Alterations in sleep architecture
  • Increased sleep fragmentation.
  • Decreased REM sleep (especially on postoperative nights one and two).
  • Decreased slow wave sleep.
  • Inverted or altered circadian rhythm cycle with peak surge in sympathetic activity between midnight and six in the morning.
  • Increased REM sleep (rebound REM; postoperative days 3–5), a stage of sleep associated with increased propensity for sleep-disordered breathing and associated bursts of sympathetic activity.

Alternations in blood biomarkers (select)
  • Increased cortisol.
  • Increased pro-inflammatory response (release of TNF-α, IL-1, IL-6, C-reactive protein).
  • Increased secretion of leptin (induces sympathetic activity, functions as an immunomodulator, in addition to regulating body adiposity).
  • Increased activation of transcription factor NF-κB and inflammatory pathways attributed to hypoxemia.
  • Decreased anti-inflammatory response such as IL-10.

OSA: Obstructive Sleep Apnea; REM: Rapid Eye Movement (REM); TJA: Total Joint Arthroplasty.

In 2001, a pivotal study published by Gupta and colleagues observed that 39% of patients diagnosed with OSA experienced post-TJA complications compared with only 19% of controls without OSA [10]. Patients having OSA were more likely to experience adverse postoperative events in general; however, given that both patients having OSA and controls without OSA experienced an adverse event, the event in the patient having OSA (approximately 22% compared with 9% in controls) was commonly cardiovascular related and included myocardial infarction, myocardial ischemia, arrhythmias and pulmonary embolus [10]. Other post-TJA complications experienced by both groups were not limited to acute hypercapnia or episodic hypoxemia, delirium, wound infections and nerve palsy [10]. Further, subanalyses revealed that patients with OSA developed 15% more serious post-TJA complications (including cardiac events requiring patient transfer to an intensive care unit [ICU]), had significantly longer length of stay (LOS), unplanned ICU days and total ICU days compared with patients without OSA [10]. Illustrating the efficacy of proper treatment, none of the 33 patients who used PAP therapy developed any complications in the first 24 h [10]. A larger, subsequent study in the US Nationwide Inpatient Sample database of 258,445 TJA patients showed that patients with OSA developed more hypoxia, had increased rates of pulmonary embolism and in-hospital mortality and higher postoperative hospital charges [9]. Other studies of post-TJA patients with OSA also observed increased adverse cardiovascular complications including development of pulmonary embolism [9,12,124], cardiac complications (nonmyocardial infarction) [13] and need for intubation/use of mechanical ventilation [12,13]. Additionally, the increased use of economic resources such as unplanned transfer to the ICU [11,13], longer hospital stays [8,13] and increased hospital costs [9] have been reported. Recognizing the growing impact that OSA has on adverse postoperative complications, the American Society of Anesthesiologists (ASA) [126] has urged providers to implement special considerations such as PAP therapy or enhanced monitoring in the postsurgical management of patients with OSA.

Given the evidence linking TJA, OSA and adverse postoperative cardiovascular outcomes, we review how the use of the blood biomarkers cTns and BNPs could represent additional information that may augment current perioperative risk stratification for a cohort of at-risk TJA patients with OSA. The literature provides notable differences among various studies evaluating cTns and BNPs in OSA patients. These differences from the studies generally relate to the clinical variability in biomarker measurement techniques as well as differences in study design. These are detailed in the ‘Limitations and challenges’ section.

Cardiac troponins: a marker for cardiovascular risk

Troponin is a protein complex involved in muscle contraction that is comprised of three distinct subunits: troponin T (cTnT), troponin I (cTnI) and troponin C (cTnC) [105]. The troponin T (largest subunit; 37–39 kiloDalton) and troponin I (26 kiloDalton) isoforms are specifically involved in cardiac muscle contraction, while the troponin C isoform is involved in cardiac as well as skeletal muscle contraction. With myocardial injury, ischemia or necrosis, cardiac cell membrane integrity is interrupted and cardiac troponins T and I are released from myocytes into the blood stream. Elevation in either cTnT or cTnI is universally accepted as a highly sensitive laboratory measure in the diagnosis of myocardial infarction [105]. Cardiac troponins (cTnT or cTnI) can be detected in the blood within 2–4 h of myocardial damage and may persist for up to 21 days [75,105]. Increased serum and plasma levels of troponin can also be seen during open heart surgery, percutaneous coronary intervention, pulmonary embolism, end-stage renal disease, pericarditis, myocarditis, aortic dissection, acute heart failure, strenuous exercise, chest wall trauma, cardiac contusion, chemotherapy, malignancy, inflammation, stroke, sepsis, subarachnoid hemorrhage and rhabdomyolysis [105,127]. In addition to underlying disease states, the variability in sample processing, differences in manufacturing methods and variation in the generation of cTn product measured (e.g., fourth generation cTnT or high sensitivity cTnT [hs-cTnT]) may all affect interpretation of results [105,128].

Troponins as a marker of cardiovascular risk in noncardiac surgery

Most of the studies that have investigated the role of perioperative measurement of cTns evaluated patients undergoing noncardiac surgery, rather than solely on TJA, and were assessing for myocardial injury [23,26,28] and infarction [21–27] (see Table 1). These studies have a great deal of heterogeneity in the specific assays and timing of troponin measurement, as well as specific populations within the larger grouping of noncardiac surgery. Thus, this review focuses on several of the larger and more applicable studies. However, overall, several studies have shown that elevated cTn levels predicted or were associated with 30-day mortality [23,27,29–31] and long-term (up to 5 years) morbidity [32] or mortality [21,24,33,34]. These studies share similarities in their limitations, strengths and weaknesses, and the majority of such findings are grouped under the ‘Limitations and challenges’ section unless as discussed below.

Table 1.
Troponins as a marker of cardiovascular risk in noncardiac surgery.

One of the largest studies to date, the Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION), evaluated levels of cTnT (using a fourth generation assay) drawn 6–12 h following surgery and during the first three postoperative days within 15,133 older adult patients (aged ≥45 years) undergoing noncardiac surgery [31]. The investigators found that higher peak levels of cTnT over the follow-up period were associated with increased risk of 30-day mortality [31]. Specifically, compared with the 1% of patients with cTnT levels ≤0.01 ng/ml, 4% of patients with cTnT levels of 0.02 ng/ml, 9.3% of patients cTnT levels between 0.03 and 0.29 ng/ml and 16.9% of patients with cTnT levels ≥0.30 ng/ml died within 30 days of surgery [31]. Forty five percent of these deaths were vascular in origin. Risk factors associated with increased 30-day mortality and increased cTnT levels included advanced age, the need for emergent surgery or major general surgery and the presence of recent coronary arterial disease. Neither OSA diagnosis (based on interviews and medical record review) nor major orthopedic surgery (20.4% of surgeries studied) was significantly associated with either 30-day mortality or increased cTnT. The authors concluded that given that the median time from elevation of cTnT at 0.02 ng/ml to death was 13.5 days, there could be sufficient time for the initiation of special considerations and potential interventions in the perioperative phase in order to minimize mortality [31]. Despite the large sample size of the study, several specific limitations include the lack of cTnT collected before surgery, the lack of association between cTnT to changes in renal function such as the estimated glomerular filtration rate in the perioperative period, and a record of any interventions that may have occurred with findings of a critical value of cTnT [31].

In a subsequent analysis of 15,065 patients in the same cohort, the VISION investigators found that 8% of patients met criteria for myocardial injury (evidenced with cTnT optimal discriminatory point levels > 0.03 ng/ml) within the first 2 days following surgery [30]. Myocardial injury was not only an independent predictor of 30-day mortality, but was also the population with the highest attributable risk toward primarily cardiovascular-related perioperative complications [30]. However, 58% of those patients who had evidence of myocardial injury did not meet criteria for the universal definition of myocardial infarction and only 15.8% of patients who met criteria for myocardial injury exhibited symptoms of cardiac ischemia [30]. A limitation in this study included the potential of missed cases of ischemic events as the study analyzed a higher optimal discriminatory threshold level of the cTnT assay (peak of 0.04 ng/ml compared with 0.03 ng/ml). Similarly, in a study of 8351 patients who underwent elective noncardiac surgery, the PeriOperative ISchemic Evaluation (POISE) trial, increased cTn (unspecified generation) levels, drawn 6–12 h following surgery and during the first three postoperative days, were associated with myocardial ischemia in patients who suffered both symptomatic and asymptomatic postoperative MI [27]. Most events related to myocardial infarction or ischemia occurred within 48 h postsurgery [27].

Other studies have found increased levels of cTnI or cTnT (including hs-cTnT), drawn preoperation and or for any of the first three mornings postoperation [21,23,24,26,28,32], or for at least two consecutive days postoperation [22,25,34] were helpful in identifying risk for postoperative cardiac complications for up to 1 month [23,25,26,28,29], 1 year [32] and up to 5 years [21,24,34] following surgery. In addition to increased postoperative morbidity, both cTnI and cTnT or hs-cTnT have been associated with identifying increased risk of mortality. A systematic review and meta-analyses found that increased cTn levels following surgery were an independent predictor of mortality within 1 year [33]. Furthermore, increased postoperative cTnI [23,24,28,29] and cTnT or hs-cTnT [21,27,30,31,34] levels predicted or are associated with decreased 5-year [34], 1–3 year [21,23,24] and 30-day survival [27,29–31].

Troponins as a marker of cardiovascular risk in TJA

The majority of the data in orthopedic surgery patients are from those undergoing emergency procedures, such as those necessitated by hip fractures [48–55], rather than elective arthroplasty. Data from this select population may not be generalizable to patients undergoing elective TJA. Reasons not only include differences in clinical and patient characteristics, but also because levels of cTns drawn from patients undergoing emergency TJA may be higher than those having elective TJA, as muscle injury associated with fractures may further raise levels of cTns [55]. Specifically, cTns rise following elective TJA in only 0.0–8.9% of patients, but do so after hip fractures in 22–52% of patients [55]. Several of these studies also found that increased perioperative (either pre- and or post-) cTn levels predicted postoperative cardiac complications that may not correlate to electrocardiographic changes [52], however did correlate with in-hospital cardiac events [50,55] and 1-year mortality [49,50]. Nevertheless, one study found that in older adults (age 85 ± 9.6 [mean ± SD] years) with multiple comorbidities, cTnI levels did not predict 6-month mortality or cardiac complications [53].

Very few studies evaluated cTns following elective TJA. These results are summarized in Table 2. In a mixed group of elective (approximately 51% of all surgeries performed in this study) and emergent hip surgery, increased cTnI was associated with in-hospital myocardial ischemia, acute coronary syndrome and other cardiac events [56]. Importantly, increased cTns were evident in patients who did not exhibit clinical symptoms of underlying cardiac perturbations, but who had a history of co-morbid cardiovascular risk factors that were likely to increase risk of cardiac events [56]. Further, increased cTnI levels were associated with mortality at 1-year and a tenfold risk of cardiac events at 1 year; however, this was primarily observed in nonelective TJA patients [56]. Thus, these biomarkers could represent an additional mechanism for identifying at-risk patients, beyond standard medical history and clinical symptoms.

Troponins as a marker of cardiovascular risk in OSA

Studies observing the association between cTns and OSA have been conflicting. Increased levels of cTns have been found to be independently associated with severity of OSA and in patients with OSA having a history of coronary artery disease (see Table 3) [60,66,67,72,129,130]. However, several studies have also found no association between levels of cTns and OSA [65,131–134]. One of the largest nationally conducted cross-sectional studies of middle aged to older adults (involving 1645 patients with a mean age of 60 years), the Atherosclerosis Risk in Communities (ARIC) and the Sleep Heart Health Study (SHHS) studies, found increased levels of hs-cTnT were independently associated with both OSA severity and risk of death or occurrence of heart failure in all OSA classified groups [66]. The association of increased levels of hs-cTnT and OSA in this study remained significant after adjusting for 17 major confounders including age, BMI, smoking status, alcohol intake, hypertension, diabetes, chronic lung disease, pulmonary function tests, estimated glomerular filtration rate, systolic blood pressure and blood levels of total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides and insulin [66].

Studies have suggested that the association between cTns and OSA is higher specifically in patients with OSA who have a known history of existing heart disease or a constellation of known cardiovascular risk factors [60,61,66,72,129,130]. In a 2014 cross-sectional study using only OSA patients from the Akershus Sleep Apnea Project (ASAP) cohort (AHI >5), Einvik and colleagues found that after adjustment for age, gender, CAD and a host of factors associated with cardiovascular risk, increased OSA severity and nocturnal desaturations were independently associated with increased levels of hs-cTnI [60]. The authors concluded that over time repeated episodes of hypoxemia could have contributed to changes in myocardial structure that consequently contributed to the release of cTns [60]. Additionally, the authors state, the use of a high-sensitive assay could have been more useful in detecting the smaller sized cTnI molecule [60]. However, after controlling for potential confounding variables (such as age, sex, hypertension, diabetes and other cardiovascular risk factors) other studies have not corroborated this finding [131,132]. Using data from the ASAP cohort, Randby and colleagues examined three groups of OSA patients and observed that the prevalence of elevated hs-cTnT increased in proportion with severity of OSA [67]; however, this association was no longer significant after adjusting for covariates such as age, sex, hypertension and diabetes [67]. Interestingly, in a 2014 cross-sectional study using only OSA patients from the ASAP cohort (AHI >5), Maeder and colleagues did not find any differences in levels of hs-cTnI in a group with severe OSA compared with a group with mild OSA [136]. Hall et al. also did not observe any significant differences in levels of hs-cTnT or a single molecule cTnI when comparing patients with varying severity of OSA to controls without OSA [132].

Further illustrating the discrepancies in the literature examining cTns in OSA, a recent study by Shah and colleagues has focused on the phenomena of ischemic preconditioning developing over time from repeated cycles of hypoxia and re-oxygenation. This confers an element of cardio-protection and results in decreased cardiac injury and hs-cTnT (third generation) levels in patients with OSA [137]. However, further studies are necessary to confirm this hypothesis.

The role of PAP therapy & troponins

Data evaluating the impact of PAP therapy, the mainstay treatment of OSA, on cardiac cTns are limited and mixed. Current evidence (see Table 3) primarily suggests that PAP adherence does not affect cTns [133–135] in the overall OSA population. However, one study showed a change in the levels of cTn, an increase in hs-cTnT levels with CPAP use [130].

In a small study of 21 patients with severe OSA and presence of CAD, Valo and colleagues found that levels of hs-cTnT drawn before and after sleep were not affected by one night of CPAP use [135]. Further, in this study, electrocardiogram monitoring of ST segments were conducted throughout the night of sleep to document any evidence of myocardial ischemia [135]. Although use of CPAP reduced ST segment depression during the lowest point of oxygen desaturation with sleep, this finding was not significant. The authors concluded that attenuation of ST segment depression could have been more evident at alternate time-points of sleep such as during post-apnea tachycardia or with an alternate measurement interval. Similarly, Maeder et al. and Cifci et al. did not find an association between hs-cTnI or cTnI levels and use of CPAP over one night or 6 months, respectively [134,136]. In a CAD naive population, Colish and colleagues found no change in levels of a third-generation cTnT from baseline following 1 year of CPAP therapy in patients with severe OSA. However, in this study both echocardiography and cardiac magnetic resonance imaging revealed that CPAP use contributed to improvements in cardiac remodeling properties and reversal of systolic and diastolic changes as seen with pulmonary hypertension in as early as 3 months, with continued improvements at 1 year [133].

In an interesting finding, Barcelo and colleagues found an unanticipated increase in hs-cTnT levels after treatment with PAP for 12 months, compared with controls without OSA [130]. Subjective assessment of PAP adherence was not explicitly described in this study, and as such this may impact interpretation of the results. The study was conducted in a male population with OSA and hypertension (including elevated glucose and triglycerides in the OSA group), but excluded patients with prior myocardial infarction, unstable angina, stroke and most of other cardiovascular-related co-morbidities. Potential mechanisms by which PAP therapy may in fact raise hs-cTnT levels have been suggested and include cardiac adaptation, turnover of cardiomyocytes and a reversible change in the membrane permeability of cardiomyocytes, along with variations in intrathoracic pressures leading to increased hs-cTnT levels. The rise in this biomarker may therefore signal a repair process or evidence of cardiac stress that could occur with PAP therapy within this particular subgroup [130].

Brain natriuretic peptides: a marker of cardiovascular risk

Brain natriuretic peptide (BNP) belongs to a group of vasodilator and anti-proliferative neurohormonal natriuretic polypeptides that are produced primarily by the cardiac ventricles (and in lesser amounts by the brain and adrenal glands) in response to stretching of cardiac myocytes or increased cardiac wall stress [139]. ProBNP, a biologically inactive prohormone, is secreted by the ventricles in response to ventricular dysfunction and cleaved into the physiologically active BNP and the biologically inactive N-terminal fragment (NT-proBNP) [139]. BNP has a half-life of approximately 20 min, and is cleared actively and passively through the renal system. NT-proBNP has a plasma half-life of approximately 2 h, and is cleared primarily through the renal system (as well as through muscles and the liver) [139]. BNP and NT-proBNP increase with age, and are found in higher levels in women and in lower levels in patients who are obese [139]. BNPs are established hallmark biomarkers in the detection of acute or chronic congestive heart failure. Their levels are independently associated with major cardiovascular events such as myocardial infarction, stroke and unstable angina in patients aged 50–89 years [140], and 1-year mortality in patients with congestive heart failure or acute coronary syndrome [141]. Elevated BNP levels can also be seen with valvular heart disease, atrial fibrillation, pulmonary embolism, severe pulmonary hypertension, inflammatory cardiac disease, acute or chronic renal failure, liver cirrhosis, sepsis, trauma, endocrine disorders, severe neurological disorders such as stroke and subarachnoid hemorrhage [139].

Brain natriuretic peptides as a marker of cardiovascular risk in noncardiac surgery

Studies measuring BNPs in patients undergoing noncardiac surgery have investigated the role in the perioperative period for risk prediction or associations with adverse postoperative myocardial events [35–44], prolonged hospital stay [45] and mortality [24,46,47] (see Table 4). Most of the studies evaluating BNPs had levels drawn within 2 weeks prior to the day of surgery, typically at one time-point, however recent studies have incorporated perioperative BNP levels (levels drawn preoperatively and up to 5 days following surgery) [36,38,43,45,46]. Preoperative BNPs have been found to be an independent predictor or associated with increased postoperative cardiac events [35–44,47,142] or mortality [24,41,46,47] in noncardiac surgery, including cardiac morbidity at 30 days following discharge from hospitalization [38]. Additionally, postoperative BNPs [36,45] were associated with cardiac events, but not always [47], and predictive for mortality over a 2-year follow-up [47]. These findings were typically representative of patients who were aged 60 years and older with cardiovascular co-morbidities.

Compared with cTns, studies evaluating BNPs in noncardiac surgeries have fewer number of patients enrolled. A study by Dernellis and colleagues, with the most number of patients (1590) noted increased preoperative BNP levels independently predicted cardiac death as well as a host of adverse cardiac events [41]. The majority of patients (40%) underwent elective orthopedic-related surgeries [41]. Further, in Dernellis’ study, increased preoperative BNP levels were superior to clinical categorization for ascertaining risk for adverse postoperative events including cardiac death [41]. The authors of this study utilized findings regarding BNP levels to alter the clinical management and treatment of patients thus confounding the study results [41]. In a study of older patients (median age of 70 years) with a host of cardiac diseases, Goei et al., observed that after adjusting for cardiac risk factor, procedure type and location of surgery, increased levels of preoperative NT-proBNP increased the odds (by fourfold) of predicting postoperative cardiovascular events including cardiac death within 30 days following surgery [37]. Increased presence of cardiac risk factors was associated with increased risk of cardiac events [37]. The authors noted that the longer half-life of NT-proBNP compared with BNP may make NT-proBNP superior to BNP in select cohorts in the screening for cardiac risk [37].

Several studies utilizing perioperative BNPs have focused on vascular surgery patients. In a study of 788 patients undergoing vascular surgery, Biccard et al. observed increased preoperative BNP levels were superior to alternate biomarkers such as C-reactive protein and cTnI in predicting overall risk for adverse postoperative cardiac events independent of the clinical oriented Revised Cardiac Risk Index (RCRI) [142]. Utilizing a Holter heart monitor in the perioperative period to detect presence of myocardial ischemia in 318 of their patients, the authors found no significant findings between BNP and Holter monitor analysis [142]. In a smaller study, also of vascular patients, increased preoperative BNP levels along with the RCRI were independent predictors of postoperative cardiac events as evidenced by elevated levels of cTnI [35]. Further, in this study, increased levels of preoperative BNP improved the overall risk classification for postoperative cardiac complications [35]. A study by Yang and colleagues in high-risk vascular patients observed that the use of preoperative levels of NT-proBNP was not significantly different compared with the use of RCRI in screening for cardiac risk; however, NT-proBNP levels predicted postoperative cardiac events such as heart failure, MI and cardiovascular death [44]. Further, to improve the power of detecting asymptomatic cardiac events, the authors validated the use of NT-proBNP levels in conjunction with the use of myocardial stress thallium test [44].

Other studies evaluating preoperative BNPs have also observed that increased levels were associated or predicted the following: adverse postoperative cardiac complications within 30 days following abdominal surgery [38], and up to 6 weeks post vascular surgery [40]; a 3.4-fold odds of having myocardial injury post-vascular surgery [39]; and, increased risk of postoperative cardiac events in patients aged 68 ± 8 years undergoing nonvascular surgeries [42]. In addition to increased postoperative morbidity, preoperative BNP has been associated with predicting postoperative mortality and long-term survival in vascular and laparotomy patients [46]; whereas, preoperative NT-proBNP has been associated or predicted postoperative all-cause mortality over a 2-year follow-up in a vascular surgery cohort [47], and a 3.5-fold odds of death [24], 6.9-fold odds of cardiovascular related mortality following vascular surgery [24].

Fewer studies have found utility in the use of postoperative BNPs in the perioperative patient. Rajagopalan and colleagues observed, increased postoperative levels of NT-proBNP in vascular surgery patients predicted mortality over a follow-up of 2 years; however, NT-proBNP levels were not associated with postoperative cardiac events [47]. Borges and colleagues found, in intermediate and high-risk vascular patients, although both preoperative and postoperative levels of NT-proBNP were associated with postoperative cardiac events in the unadjusted model, preoperative but not postoperative levels was associated with a fourfold odds of adverse major postoperative cardiac events after adjusting for clinical factors [36]. The authors concluded although postoperative NT-proBNP levels were increased, there was lack of significance potentially attributed to the perioperative release of surgery-related catecholamine contributing to subtle postoperative myocardial ischemia and elevation of NT-proBNP levels in a higher cardiac risk cohort [36]. This finding was similar to a study by Schutt et al., who observed increased preoperative NT-proBNP but not postoperative NT-proBNP levels were associated with postoperative cardiac events; however, increased postoperative levels of NT-proBNP were common in all patients [43].

There are several meta-analyses and systematic reviews of studies evaluating BNPs in the surgical population; and they consistently demonstrate that BNPs, in particular when drawn preoperation compared with postoperation, are independent predictors of both short- and long-term adverse cardiac events, including cardiac deaths and all-cause mortality [143,144]. In addition, BNPs were found to be useful as a stratification tool to assess risk for postoperative cardiovascular complications [145]. A meta-analysis of vascular surgery patients found that increased preoperative BNP levels (including NT-proBNP) were associated with increased risk of 30-day postoperative cardiac events, cardiac-related mortality and all-cause deaths up to 180 days [144]. Using preoperative BNPs significantly improved the preoperative predictive risk classification of the traditionally utilized RCRI [145]. Furthermore, higher postoperative BNP levels obtained from 1 h to 7 days postoperation following noncardiac surgery (primarily vascular surgery but also included emergent and elective orthopedic surgery), were independently associated with nonfatal myocardial infarction, cardiac failure, cardiac mortality, cardiac arrest and all-cause mortality [146]. Another meta-analysis evaluating the role of BNPs following major noncardiac surgery found that increases in both preoperative BNP and NT-proBNP identified patients at risk for myocardial injury, nonfatal myocardial infarction, all-cause mortality and cardiac death [143]. Further in this study, preoperative BNP was also associated with increased risk for major adverse cardiovascular events and all-cause mortality that occurred within 6 months following surgery [143]. Last, a recent systematic review and meta-analysis found that in the noncardiac surgery patient population, increased postoperative BNP levels were the strongest predictors of nonfatal MI and death at 30 days and ≥180 days following surgery, adding prognostic value in risk stratification for postoperative complications [147].

Brain natriuretic peptides as a marker of cardiovascular risk in TJA

Data regarding the role of BNPs in predicting future cardiovascular risk in TJA, like the data regarding cTns, largely comes from patients having emergency procedures (e.g., those following acute fractures) with a cohort that includes non-TJA surgeries [57,58,148] rather than elective procedures [45]. As with cTns, four studies showed that a rise in NT-proBNP levels after emergency TJA predicts in-hospital cardiac events [129,134] and increased 1- [128,129] and 2-year [130] mortality in patients aged 60–86 years, but did not predict 6-month mortality or cardiac complications in older adults aged 85 ± 9.6 years [132], who may have other competing co-morbidities.

Table 5 summarizes data from studies that evaluated BNPs following elective TJA. These studies suggest that increased BNPs predicted in-hospital myocardial ischemia, injury and fatal cardiovascular events.

BNPs added value in scenarios where patients did not report clinical symptoms of a cardiac condition, but who had a history of cardiovascular risk factors. Thus, BNPs may be more valuable than standard clinical symptoms in predicting cardiovascular risk. In the singular study of older patients (aged 73.12 ± 10.05 years) with hypertension who underwent elective TJA, Park and colleagues observed increased postoperative but not preoperative levels of BNP predicted length of hospital stay that was ≥ 30 days; however, BNP levels were not associated with adverse postoperative cardiac events [45]. The majority of patients in Park and colleagues’ study were women who did not have extreme cardiovascular risk factors (such as stroke and ischemic heart disease) [45].

Brain natriuretic peptides as a marker of cardiovascular risk in OSA

The majority of studies evaluating BNPs in patients with OSA found no association between levels of BNP and OSA severity [62,64,66,69–71,73,133,134,149,150], although some studies have found an association [63] (see Table 6). Association between BNP levels and OSA severity appears most useful in select sub-groups including a cohort of only women, or in patients with varying severity of coronary artery disease (CAD).

Notably, in the largest study conducted to date with 1645 patients, the ARIC-SHHS study did not find an association between NT-proBNP levels and the severity of OSA in their subjects, despite adjusting for 17 confounders [66]. The authors concluded that the association between OSA severity and NT-proBNP was confounded by BMI. Although, statistical adjustment for BMI reduced the negative association between OSA and NT-proBNP levels, this finding was not significant following further adjusted analysis [66]. Similarly, in a community cohort with stable cardiovascular risk from the Framingham Offspring Study, Patwardhan and colleagues also did not find an association between OSA severity and BNP nor NT-atrial NP (a marker belonging to the natriuretic peptide family that is sensitive to stimuli contributing to cardiac atrial stretch) [151]. The authors conclude that timing of the blood draws (between 8 and 9 in the morning), sample selection bias or the prolonged time between when BNP levels were drawn and PSG (median of 79 days) could have all affected the final findings [151]. In a cohort of patients with some cardiovascular co-morbidities, Vatany and colleagues observed, NT-proBNP levels decreased following a night's sleep compared with the morning-after levels but this finding was not significant [71].

Studies evaluating the utility of BNP levels and OSA severity in patients with background CAD have been informative. Valo and colleagues observed in patients with untreated OSA, NT-proBNP levels did not significantly change when compared before sleep to after sleep; however, levels in patients with OSA and background CAD were higher than in those with OSA without a history of CAD [131]. Maeder et al., observed overnight BNP but not NT-proBNP levels had a larger relative (but not absolute) reduction following sleep in patients with moderate/severe OSA compared with those with mild/no OSA [136]. Patients with moderate/severe OSA were mostly male and on a beta-blocker medication [136]. The authors postulate that the lack of affect observed in NT-proBNP levels may be attributed to differences in half-life between the two BNPs (longer for NT-proBNP) and distinct individual biological variability that may be present [136]. In patients with stable CAD, NT-proBNP levels were not only increased but correlated with severity of coronary stenosis [136]. Other studies have found although there were no differences in levels of BNP between moderate compared with severe OSA groups, BNP levels grouped by quintile were associated with improvement in cardiac architecture such as left ventricular hypertrophy [70]. In a interesting community-based study evaluating the effect of OSA severity and levels of morning BNP in a women only cohort, Ljunggren and colleagues observed that mean BNP levels (drawn in the morning following sleep) increased as the severity of OSA increased (further associated with oxygen desaturation index levels implying a dose–response relationship) [63]. The authors conclude BNP levels could have been affected by episodes of hypoxia during sleep [63].

The role of PAP therapy & brain natriuretic peptides

The effects of PAP therapy on BNP levels have been mixed, with a number of studies demonstrating PAP did not significantly alter levels of BNPs [64,73,133,134] versus other studies observing PAP decreased levels of BNPs [62,69,135,149] (see Table 6). However, some evidence seems to suggest that significant changes in BNP levels with PAP therapy occurs, particularly in patients with OSA and known left ventricular dysfunction or who have pre-existing cardiovascular risk factors.

In evaluating a number of biomarkers including BNP and NT-proBNP levels drawn pre-and post-one night of CPAP in a cohort with moderate-to-severe OSA, Maeder and colleagues did not observe significant findings [136]. Zhao and colleagues observed a reduction in high sensitivity C-reactive protein levels but not in NT-proBNP levels following 3 months of CPAP in a cohort of patients with CAD and severe OSA who were previously CPAP naive [73]. In an interesting discussion, the authors observe how medications used to treat CAD may blunt or reverse OSA-related cardiac strain, thus potentially contributing to the lack of association seen with NT-proBNP levels [73]. Cifci et al., also did not observe an association between pro-BNP levels and OSA severity or the use of CPAP following 6 months of therapy. The authors acknowledge adherence to CPAP was evaluated subjectively [134] and may have a role in their findings.

Other studies have observed that although BNP levels were unaffected, initiation of CPAP [133] or nasal CPAP [64] improved cardiac structure and cardio-respiratory physiology including left ventricular mass size and pulmonary hypertension (improvements seen at 3 months and up to 1 year) [133] or peak maximal oxygen consumption and heart rate recovery (following approximately 8 months of PAP therapy) [64]. This phenomena was also observed by Hubner and colleagues, who did not find any association between NT-proBNP levels and OSA severity either before or after nasal or bi-level CPAP; however, NT-proBNP levels were associated with impaired left ventricular ejection fraction and systemic arterial hypertension [149]. NT-proBNP levels were reduced following nasal CPAP in a handful of patients but this finding was not significant quite possibly due to the small number of patients in this subgroup [149].

Last, several studies have observed changes in BNP levels that were associated with PAP use. Valo and colleagues observed, not only did a night of CPAP therapy reduce NT-proBNP levels in patients with severe OSA with presence of CAD, it decreased ST-segment depression monitored at the time of peak oxygen desaturation during sleep [135]. Koga et al., observed BNP levels decreased following 3 months of nasal CPAP [62]. Further, prevalence for global left ventricular dysfunction decreased significantly in the treated OSA group [62]. Finally, although Tasci and co-workers did not observe any changes in baseline NT-proBNP levels between hypertensive and normotensive OSA groups compared with controls without OSA, use of CPAP reduced NT-proBNP levels in both groups, especially in the hypertensive group [69].

Limitations & challenges

Overall, studies of cTn and BNP levels utilized as risk stratification tools or predictors of outcomes in patients with OSA undergoing TJA are lacking. Recommendations for the use of cTn and BNP levels in the diagnosis of acute coronary syndromes or other etiologies have been established by the National Academy of Clinical Biochemistry laboratory medicine practice guidelines [61], and the European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for Universal Definition of Myocardial Infarction [77]. However, the routine use of cTns and BNPs to stratify risk for cardiovascular events following surgical procedures remains in its early stages and is currently being explored as delineated in this review.

There are many limitations in existing research that must be considered prior to the use of cTns or BNPs for outcomes in the patient with OSA presenting for TJA. These limitations and challenges derived from the studies presented can be categorized into the following: clinical use of biomarkers and study design.

Clinical use of biomarkers

Earlier studies utilized different generations of cTn or BNP assays that may have had a role in the preciseness of the assay results and thus offer conflicting results. Additionally, fundamental differences in the size of cTnI versus cTnT to facilitate the subtle detection of myocardial injury may be an issue. Pathophysiological differences in the release or clearance mechanisms of both cTns and BNPs could affect detection of circulating concentrations. Further, the interchangeable use of either plasma or serum samples, the timing of when the biomarker is drawn in consideration of sleep architecture, the inconsistent number of blood samples obtained during each study, variation in time points of blood sample collection, variation in elapsed time from collection to performance of the assay contributing to the stability or degradation of proteins, lack of synchronous collection of biomarkers during PSG recordings and consideration in half-life difference between BNP and NT-proBNP may have effected study results and comparison of studies.

Study design

Most of the studies consisted of small sample sizes, exhibited selection bias, lacked subject randomization, lacked objective measures to evaluate myocardial function such as echocardiography, varied in the severity and duration of OSA of the subject population, lacked control for adherence to PAP therapy, and varied in the presence of baseline cardiovascular disease or risk factors. Additionally, the nature of disease manifestation leading to surgery itself may have an effect on results.

Other limitations to be addressed include differentiating whether cTns or BNPs could guide medical care and whether these markers are better utilized as a surrogate marker for cardiovascular risk stratification in the preoperative or postoperative setting. Most importantly, studies would have to explore the variability in preoperative or perioperative cTns or BNPs and if these levels are predictive of worse postoperative cardiovascular outcomes in specific subgroups of surgical patients.

Future research directions

Given the evidence illustrating the association of cTns and BNPs and cardiovascular events in patients undergoing noncardiac and TJA surgeries, and in select patients with OSA, future studies should explore the role of cTns and BNPs as potential tools to stratify patients with OSA having TJA who are at increased risk for cardiovascular morbidity. Studies should focus on several key areas. First, they should assess whether cTns and BNPs could be used as part of a preoperative risk stratification algorithm in order to predict postoperative cardiovascular complications. Second, studies should explore whether using novel clinical management pathways that incorporate perioperative cTns and BNPs in TJA patients with OSA can reduce postoperative cardiovascular complications, as well as healthcare utilization, length of stay and medical costs. Such studies should explore the impact of perioperative cTns and BNPs for the perioperative patient with OSA in TJA concomitant with use of the guidelines recommended by the ASA, American College of Cardiology/American Heart Association (ACC/AHA) or the European Society of Cardiology/European Society of Anaesthesiology (ESC/ESA), AASM and American College of Physicians [84,85]. Both the ACC/AHA and ESC/ESA have explored the role of sleep apnea and the use of biomarkers, separately, in evaluating risk of the development of postoperative cardiovascular complications.

Finally, future studies evaluating the potential independent association between perioperative cTns or BNPs in OSA patients who undergo TJA and the risk for developing primary cardiovascular (e.g., acute myocardial infarction or nonmyocardial infarction cardiac complications), pulmonary (e.g., pulmonary embolism) and infectious complications (e.g., pneumonia, sepsis and periprosthetic joint or wound infection) would be helpful [1,83].


Data from studies presented here examining levels of cTns and BNPs suggest that these markers appear useful in identifying the subset of patients who are most likely to experience postoperative cardiovascular complications while undergoing noncardiac surgery, including TJA. In particular, results suggest these biomarkers may perform best in patients who are older (age>60) and/or have underlying cardiovascular disease or risk factors. However, we have very limited and inconclusive evidence about the role of these biomarkers in predicting cardiovascular risk in the subgroup of patients who have OSA at the time of surgery. This gap in our knowledge exists in the face of rising numbers of patients with background OSA who have elective TJA. The limited evidence we do have, however, hints that patients who are older and have a higher risk or presence of cardiovascular disease (attributes that are common in TJA and OSA) are more likely to have increased postoperative cardiovascular morbidity or mortality. Some evidence, albeit conflicting, also suggests that this increased risk is associated with elevations in cTns and or BNPs. Further data are needed to confirm whether these biomarkers, measured perioperatively in the patient with OSA undergoing TJA, may indeed differentiate patients at highest risk for adverse postoperative cardiovascular complications and death.

Present trends show that patients having TJA are older and more obese than in prior years, a group that is at particular risk for OSA and its potential downstream cardiovascular complications, which are higher still following surgery. Given that preliminary data support a role for biomarkers in predicting this cardiovascular risk, future studies should address a further exploration and refinement of the role of these biomarkers in patients having TJA.

Executive summary

Obstructive sleep apnea (OSA) is a risk factor for postoperative cardiovascular complications, increased health care utilization and negative downstream economic costs in patients undergoing elective total hip and knee joint arthroplasty (TJA)

  • Obstructive sleep apnea (OSA) is highly prevalent and a risk factor for major postoperative cardiovascular complications, including lethal arrhythmias, thromboembolism and death in adult patients undergoing total hip and knee joint arthroplasty (TJA).
  • Failure to implement special considerations in the perioperative clinical management of the TJA patient with OSA may also lead to increased postoperative healthcare utilization (transfers to an intensive care unit), length of stay, costs and medical litigation.

Perioperative risk stratification for postoperative cardiovascular complications in patients undergoing TJA & having OSA remains inadequate

  • Despite guidelines established by the American Society of Anesthesiologists, many patients at risk or having OSA and undergoing TJA are not stratified as at risk for increased postoperative complications.
  • The number of patients presenting for TJA are rising while there are limited resources to efficiently stratify those at risk for developing post-TJA cardiovascular-specific complications.

Perioperative cardiac troponins (cTns) & brain natriuretic peptides (BNPs) may help stratify risk for postoperative cardiovascular complications in the TJA patient having OSA

  • Cardiac biomarkers such as cTns and BNPs are associated with OSA and also predictive of postoperative cardiovascular complications and death in patients having noncardiac surgery including TJA.
  • The utility of cardiac biomarkers, cTns and BNPs, in OSA patients undergoing TJA remains undefined and should be explored.

Future perspective

  • In patients undergoing TJA and having OSA, future research should attempt to:
    • – Develop efficient ways to identify those patients who are at highest risk for having postoperative cardiovascular complications, and evaluate whether perioperative measurement of biomarkers such as cTns and BNPs has a role in such risk assessment.
    • – Develop and evaluate the utility of perioperative management protocols for OSA, which may include cTns and BNPs, in reducing postoperative cardiovascular complications, healthcare utilization and medical costs.


The authors thank Mr Craig Diena at the Center for Sleep and Circadian Neurobiology, Perelman School of Medicine, University of Pennsylvania, for his assistance in manuscript preparation.


Financial & competing interests disclosure

M Melanie Lyons was funded by NIH grant T32HL07713. I Gurubhagavatula received loan of positive airway pressure devices (ResMed, Inc.) for use in a research protocol regarding management of OSA for a pilot study of sleep apnea in Philadelphia police officers. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.


Papers of special note have been highlighted as: •• of considerable interest

1. Bozic KJ, Grosso LM, Lin Z, et al. Variation in hospital-level risk-standardized complication rates following elective primary total hip and knee arthroplasty. J. Bone Joint Surg. Am. 2014;96(8):640–647. [PubMed]
2. Iorio R, Robb WJ, Healy WL, et al. Orthopaedic surgeon workforce and volume assessment for total hip and knee replacement in the United States: preparing for an epidemic. J. Bone Joint Surg. Am. 2008;90(7):1598–1605. [PubMed]•• The volume of total joint arthroplasty (TJA) is rising exponentially in the coming decade attributed to a growing aging and obese population. This population also has increased chronic co-morbidities.
3. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with Type 2 diabetes: the Sleep AHEAD study. Arch. Intern. Med. 2009;169(17):1619–1626. [PMC free article] [PubMed]
4. Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32(6):1017–1019. [PMC free article] [PubMed]
5. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am. J. Epidemiol. 2013;177(9):1006–1014. [PMC free article] [PubMed]•• The prevalence for obstructive sleep apnea (OSA) is rising, and 34% of middle-aged men and 17% of middle-aged women suffer from at least mild OSA, and 13 and 6%, respectively, suffer from moderate-to-severe disease. These estimates represent an increase compared with the previous decade, attributed to the rising rates of obesity and aging in the population, two major risk factors for OSA.
6. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997;20(9):705–706. [PubMed]
7. Berger G, Berger R, Oksenberg A. Progression of snoring and obstructive sleep apnoea: the role of increasing weight and time. Eur. Respir. J. 2009;33(2):338–345. [PubMed]
8. Berend KR, Ajluni AF, Nunez-Garcia LA, Lombardi AV, Adams JB. Prevalence and management of obstructive sleep apnea in patients undergoing total joint arthroplasty. J. Arthroplasty. 2010;25(Suppl. 6):54–57. [PubMed]
9. D'apuzzo MR, Browne JA. Obstructive sleep apnea as a risk factor for postoperative complications after revision joint arthroplasty. J. Arthroplasty. 2012;27(Suppl. 8):95–98. [PubMed]
10. Gupta RM, Parvizi J, Hanssen AD, Gay PC. Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study. Mayo Clin. Proc. 2001;76(9):897–905. [PubMed]•• In patients undergoing TJA, serious adverse postoperative complications, including cardiovascular related, occurred in 24% of OSA patients versus 9% in those without OSA.
11. Kamath AF, Mcauliffe CL, Baldwin KD, Lucas JB, Kosseim LM, Israelite CL. Unplanned admission to the intensive care unit after total hip arthroplasty. J. Arthroplasty. 2012;27(6):1027–1032. e1021–1022. [PubMed]
12. Memtsoudis S, Liu SS, Ma Y, et al. Perioperative pulmonary outcomes in patients with sleep apnea after noncardiac surgery. Anesth. Analg. 2011;112(1):113–121. [PubMed]
13. Memtsoudis SG, Stundner O, Rasul R, et al. The impact of sleep apnea on postoperative utilization of resources and adverse outcomes. Anesth. Analg. 2014;118(2):407–418. [PMC free article] [PubMed]•• Post-TJA patients with OSA are observed to have increased risk for adverse pulmonary and cardiac complications. Further, there is increased postoperative need for respiratory support, use of an intensive care unit as well as other special monitoring resources, and increased length of stay in the hospital.
14. Parikh SN, Stuchin SA, Maca C, Fallar E, Steiger D. Sleep apnea syndrome in patients undergoing total joint arthroplasty. J. Arthroplasty. 2002;17(5):635–642. [PubMed]
15. Cashman J, Bican O, Patel R, Jacovides C, Dalsey C, Parvizi J. Total joint arthroplasty in patients with obstructive sleep apnea: strategies for reduction of perioperative complications. Surg. Technol. Int. 2011;21:261–266. [PubMed]
16. Liu SS, Chisholm MF, Ngeow J, et al. Postoperative hypoxemia in orthopedic patients with obstructive sleep apnea. HSS J. 2011;7(1):2–8. [PMC free article] [PubMed]
17. Dempsey JA, Veasey SC, Morgan BJ, O'donnell CP. Pathophysiology of sleep apnea. Physiol. Rev. 2010;90(1):47–112. [PubMed]
18. Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J. Am. Coll. Cardiol. 2013;62(7):610–616. [PMC free article] [PubMed]
19. Gami AS, Somers VK. Implications of obstructive sleep apnea for atrial fibrillation and sudden cardiac death. J. Cardiovasc. Electrophysiol. 2008;19(9):997–1003. [PubMed]
20. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health) Circulation. 2008;118(10):1080–1111. [PubMed]•• OSA patients experience physiologic perturbations that have been linked to many cardiovascular complications, including coronary ischemia, infarction, arrhythmias, heart failure, hypertension, venous thromboembolism, stroke and even death.
21. Nagele P, Brown F, Gage BF, et al. High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. Am. Heart J. 2013;166(2):325 e321–332 e321. [PMC free article] [PubMed]
22. Borges FK, Furtado MV, Rossini AP, et al. Clinical use of ultrasensitive cardiac troponin I assay in intermediate- and high-risk surgery patients. Dis. Markers. 2013;35(6):945–953. [PMC free article] [PubMed]
23. Bursi F, Babuin L, Barbieri A, et al. Vascular surgery patients: perioperative and long-term risk according to the ACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur. Heart J. 2005;26(22):2448–2456. [PubMed]
24. Cuthbertson BH, Amiri AR, Croal BL, Rajagopalan S, Brittenden J, Hillis GS. Utility of B-type natriuretic peptide in predicting medium-term mortality in patients undergoing major non-cardiac surgery. Am. J. Cardiol. 2007;100(8):1310–1313. [PubMed]
25. Martinez EA, Nass CM, Jermyn RM, et al. Intermittent cardiac troponin-I screening is an effective means of surveillance for a perioperative myocardial infarction. J. Cardiothorac. Vasc. Anesth. 2005;19(5):577–582. [PubMed]
26. Barbagallo M, Casati A, Spadini E, et al. Early increases in cardiac troponin levels after major vascular surgery is associated with an increased frequency of delayed cardiac complications. J. Clin. Anesth. 2006;18(4):280–285. [PubMed]
27. Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann. Intern. Med. 2011;154(8):523–528. [PubMed]
28. Van Waes JA, Nathoe HM, De Graaff JC, et al. Myocardial injury after noncardiac surgery and its association with short-term mortality. Circulation. 2013;127(23):2264–2271. [PubMed]
29. Beattie WS, Karkouti K, Tait G, et al. Use of clinically based troponin underestimates the cardiac injury in non-cardiac surgery: a single-centre cohort study in 51,701 consecutive patients. Can. J. Anaesth. 2012;59(11):1013–1022. [PubMed]
30. Botto F, Alonso-Coello P, Chan MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30–day outcomes. Anesthesiology. 2014;120(3):564–578. [PubMed]•• In a study of 15,065 patients undergoing noncardiac surgery, peak postoperative cardiac Troponin levels were associated with higher risk for postoperative cardiovascular complications and 30-day mortality, and 58% of patients having myocardial injury postoperation did not meet criteria for myocardial injury based on current guidelines and only 15.8% of patients who had myocardial injury exhibited symptoms of cardiac ischemia.
31. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study I. Devereaux PJ, Chan MT, et al. Association between postoperative troponin levels and 30–day mortality among patients undergoing noncardiac surgery. JAMA. 2012;307(21):2295–2304. [PubMed]
32. Kouvelos GN, Milionis HJ, Arnaoutoglou EM, et al. Postoperative levels of cardiac troponin versus CK-MB and high-sensitivity C-reactive protein for the prediction of 1–year cardiovascular outcome in patients undergoing vascular surgery. Coron. Artery Dis. 2011;22(6):428–434. [PubMed]
33. Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. Anesthesiology. 2011;114(4):796–806. [PubMed]
34. Simons JP, Baril DT, Goodney PP, et al. The effect of postoperative myocardial ischemia on long-term survival after vascular surgery. J. Vasc. Surg. 2013;58(6):1600–1608. [PMC free article] [PubMed]
35. Biccard BM, Naidoo P, De Vasconcellos K. What is the best pre-operative risk stratification tool for major adverse cardiac events following elective vascular surgery? A prospective observational cohort study evaluating pre-operative myocardial ischaemia monitoring and biomarker analysis. Anaesthesia. 2012;67(4):389–395. [PubMed]
36. Borges FK, Furtado MV, Rossini AP, et al. Prognostic value of perioperative N-terminal pro-B-type natriuretic peptide in noncardiac surgery. Arq. Bras. Cardiol. 2013;100(6):561–570. [PubMed]
37. Goei D, Hoeks SE, Boersma E, et al. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients. Coron. Artery Dis. 2009;20(3):219–224. [PubMed]
38. Mercantini P, Di Somma S, Magrini L, et al. Preoperative brain natriuretic peptide (BNP) is a better predictor of adverse cardiac events compared with preoperative scoring system in patients who underwent abdominal surgery. World J. Surg. 2012;36(1):24–30. [PubMed]
39. Rajagopalan S, Croal BL, Bachoo P, Hillis GS, Cuthbertson BH, Brittenden J. N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. J. Vasc. Surg. 2008;48(4):912–917. discussion 917. [PubMed]
40. Gibson SC, Payne CJ, Byrne DS, Berry C, Dargie HJ, Kingsmore DB. B-type natriuretic peptide predicts cardiac morbidity and mortality after major surgery. Br. J. Surg. 2007;94(7):903–909. [PubMed]
41. Dernellis J, Panaretou M. Assessment of cardiac risk before non-cardiac surgery: brain natriuretic peptide in 1590 patients. Heart. 2006;92(11):1645–1650. [PMC free article] [PubMed]
42. Yun KH, Jeong MH, Oh SK, et al. Preoperative plasma N-terminal pro-brain natriuretic peptide concentration and perioperative cardiovascular risk in elderly patients. Circ. J. 2008;72(2):195–199. [PubMed]
43. Schutt RC, Cevik C, Phy MP. Plasma N-terminal prohormone brain natriuretic peptide as a marker for postoperative cardiac events in high-risk patients undergoing noncardiac surgery. Am. J. Cardiol. 2009;104(1):137–140. [PubMed]
44. Yang JH, Choi JH, Ki YW, et al. Plasma N-terminal pro-B-type natriuretic peptide is predictive of perioperative cardiac events in patients undergoing vascular surgery. Korean J. Intern. Med. 2012;27(3):301–310. [PMC free article] [PubMed]
45. Park JH, Shin GJ, Ryu JI, Pyun WB. Postoperative B-type natriuretic Peptide levels associated with prolonged hospitalization in hypertensive patients after non-cardiac surgery. Korean Circ. J. 2012;42(8):521–527. [PMC free article] [PubMed]
46. Payne CJ, Gibson SC, Bryce G, Jardine AG, Berry C, Kingsmore DB. B-type natriuretic peptide predicts long-term survival after major non-cardiac surgery. Br. J. Anaesth. 2011;107(2):144–149. [PubMed]
47. Rajagopalan S, Croal BL, Reeve J, Bachoo P, Brittenden J. N-terminal pro-B-type natriuretic peptide is an independent predictor of all-cause mortality and MACE after major vascular surgery in medium-term follow-up. Eur. J. Vasc. Endovasc. Surg. 2011;41(5):657–662. [PubMed]
48. Chong C, Lam Q, Ryan J, Sinnappu R, Lim WK. Impact of troponin 1 on long-term mortality after emergency orthopaedic surgery in older patients. Intern. Med. J. 2010;40(11):751–756. [PubMed]
49. Chong CP, Lam QT, Ryan JE, Sinnappu RN, Lim WK. Incidence of post-operative troponin I rises and 1-year mortality after emergency orthopaedic surgery in older patients. Age Ageing. 2009;38(2):168–174. [PubMed]
50. Chong CP, Lim WK, Velkoska E, et al. N-terminal pro-brain natriuretic peptide and angiotensin-converting enzyme-2 levels and their association with postoperative cardiac complications after emergency orthopedic surgery. Am. J. Cardiol. 2012;109(9):1365–1373. [PubMed]
51. Chong CP, Ryan JE, Van Gaal WJ, et al. Usefulness of N-terminal pro-brain natriuretic peptide to predict postoperative cardiac complications and long-term mortality after emergency lower limb orthopedic surgery. Am. J. Cardiol. 2010;106(6):865–872. [PubMed]
52. Chong CP, Van Gaal WJ, Profitis K, Ryan JE, Savige J, Lim WK. Electrocardiograph changes, troponin levels and cardiac complications after orthopaedic surgery. Ann. Acad. Med. Singapore. 2013;42(1):24–32. [PubMed]
53. Chong CP, Van Gaal WJ, Ryan JE, Burrell LM, Savige J, Lim WK. Troponin I and NT-proBNP (N-terminal pro-brain natriuretic peptide) do not predict 6-month mortality in frail older patients undergoing orthopedic surgery. J. Am. Med. Dir. Assoc. 2010;11(6):415–420. [PubMed]
54. Chong CP, Van Gaal WJ, Ryan JE, Profitis K, Savige J, Lim WK. Does cardiology intervention improve mortality for post-operative troponin elevations after emergency orthopaedic-geriatric surgery? A randomised controlled study. Injury. 2012;43(7):1193–1198. [PubMed]
55. Chong CP, Van Gaal WJ, Savige J, Lim WK. Cardiac injury and troponin testing after orthopaedic surgery. Injury. 2011;42(9):855–863. [PubMed]
56. Ausset S, Auroy Y, Lambert E, et al. Cardiac troponin I release after hip surgery correlates with poor long-term cardiac outcome. Eur. J. Anaesthesiol. 2008;25(2):158–164. [PubMed]
57. Breidthardt T, Kindler CH, Schindler C, Futterer M, Yonekawa K, Mueller C. B-type natriuretic peptide in patients undergoing orthopaedic surgery: a prospective cohort study. Eur. J. Anaesthesiol. 2010;27(8):690–695. [PubMed]
58. Villacorta Junior H, Castro IS, Godinho M, et al. B-type natriuretic peptide is predictive of postoperative events in orthopedic surgery. Arq. Bras. Cardiol. 2010;95(6):743–748. [PubMed]
59. Park JH, Shin GJ, Ryu JI, Pyun WB. Postoperative b-type natriuretic peptide levels associated with prolonged hospitalization in hypertensive patients after non-cardiac surgery. Korean Circ. J. 2012;42(8):521–527. [PMC free article] [PubMed]
60. Einvik G, Rosjo H, Randby A, et al. Severity of obstructive sleep apnea is associated with cardiac troponin I concentrations in a community-based sample: data from the Akershus Sleep Apnea Project. Sleep. 2014;37(6):1111–1116. 1116A–1116B. [PubMed]
61. Gami AS, Svatikova A, Wolk R, et al. Cardiac troponin T in obstructive sleep apnea. Chest. 2004;125(6):2097–2100. [PubMed]
62. Koga S, Ikeda S, Urata J, Kohno S. Effect of nasal continuous positive airway pressure in men on global left ventricular myocardial performance in patients with obstructive sleep apnea syndrome. Am. J. Cardiol. 2008;101(12):1796–1800. [PubMed]
63. Ljunggren M, Lindahl B, Theorell-Haglow J, Lindberg E. Association between obstructive sleep apnea and elevated levels of type B natriuretic peptide in a community-based sample of women. Sleep. 2012;35(11):1521–1527. [PubMed]
64. Maeder MT, Ammann P, Munzer T, et al. Continuous positive airway pressure improves exercise capacity and heart rate recovery in obstructive sleep apnea. Int. J. Cardiol. 2009;132(1):75–83. [PubMed]
65. Oktay B, Akbal E, Firat H, Ardic S, Akdemir R, Kizilgun M. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath. 2008;12(3):223–228. [PubMed]
66. Querejeta Roca G, Redline S, Punjabi N, et al. Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am. J. Respir. Crit. Care Med. 2013;188(12):1460–1465. [PMC free article] [PubMed]•• Increased levels of cardiac Troponin is independently linked with OSA severity suggesting evidence of subclinical myocardial injury.
67. Randby A, Namtvedt SK, Einvik G, et al. Obstructive sleep apnea is associated with increased high-sensitivity cardiac troponin T levels. Chest. 2012;142(3):639–646. [PubMed]
68. Takama N, Kurabayashi M. Effectiveness of a portable device and the need for treatment of mild-to-moderate obstructive sleep-disordered breathing in patients with cardiovascular disease. J. Cardiol. 2010;56(1):73–78. [PubMed]
69. Tasci S, Manka R, Scholtyssek S, et al. NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. Clin. Res. Cardiol. 2006;95(1):23–30. [PubMed]
70. Usui Y, Tomiyama H, Hashimoto H, et al. Plasma B-type natriuretic peptide level is associated with left ventricular hypertrophy among obstructive sleep apnoea patients. J. Hypertens. 2008;26(1):117–123. [PubMed]
71. Vartany E, Imevbore M, O'malley M, et al. N-terminal pro-brain natriuretic peptide for detection of cardiovascular stress in patients with obstructive sleep apnea syndrome. J. Sleep Res. 2006;15(4):424–429. [PubMed]
72. Won CH, Chun HJ, Chandra SM, Sarinas PS, Chitkara RK, Heidenreich PA. Severe obstructive sleep apnea increases mortality in patients with ischemic heart disease and myocardial injury. Sleep Breath. 2013;17(1):85–91. [PubMed]
73. Zhao Q, Liu ZH, Zhao ZH, et al. Effects of obstructive sleep apnea and its treatment on cardiovascular risk in CAD patients. Respir. Med. 2011;105(10):1557–1564. [PubMed]
74. Lindahl B, Venge P, James S. The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. Am. Heart J. 2010;160(2):224–229. [PubMed]
75. Group NW, Wu AH, Jaffe AS, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin. Chem. 2007;53(12):2086–2096. [PubMed]
76. Investigators VPS, Devereaux PJ, Bradley D, et al. An international prospective cohort study evaluating major vascular complications among patients undergoing noncardiac surgery: the vision pilot study. Open Med. 2011;5(4):e193–e200. [PMC free article] [PubMed]
77. Ray MJ, Calabro LJ, Sirisena T, Crawford SA, Crawford RW, Walters DL. Pre-operative platelet-bound cd40 ligand is probably associated with peri-operative cardiac events in hip and knee arthroplasty. Eur. J. Clin. Invest. 2010;40(6):497–503. [PubMed]
78. Mouzopoulos G, Kouvaris C, Antonopoulos D, et al. Perioperative creatine phosphokinase (cpk) and troponin i trends after elective hip surgery. J. Trauma. 2007;63(2):388–393. [PubMed]
79. Wang YC, Mcpherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–825. [PubMed]
80. Control CFD. Public health and aging: trends in aging-United States and worldwide. Morb. Mortal. Weekly Rep. 2003;52(6):101–106. [PubMed]
81. Harkess JWaC JR. Arthroplasty of the Hip. In: Canale ST, editor. Campbell's Operative Orthopaedics. Mosby, Elsiever; 2013. pp. 158–310.
82. Mihalko WM. Arthroplasty of the Knee. In: Canale ST, editor. Campbell's Operative Orthopaedics. Mosby, Elsiever; 2013. pp. 376–444.
83. Kirksey M, Chiu YL, Ma Y, et al. Trends in in-hospital major morbidity and mortality after total joint arthroplasty: United States 1998–2008. Anesth. Analg. 2012;115(2):321–327. [PubMed]
84. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 2014;64(22):e77–e137. [PubMed]
85. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) Eur. J. Anaesthesiol. 2014;31(10):517–573. [PubMed]
86. Udwadia ZF, Doshi AV, Lonkar SG, Singh CI. Prevalence of sleep-disordered breathing and sleep apnea in middle-aged urban Indian men. Am. J. Respir. Crit. Care Med. 2004;169(2):168–173. [PubMed]
87. Epstein LJ, Kristo D, Strollo PJ, Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J. Clin. Sleep Med. 2009;5(3):263–276. [PubMed]
88. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 2006;173(8):910–916. [PMC free article] [PubMed]
89. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62(16):e147–e239. [PubMed]
90. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ. 2000;320(7233):479–482. [PMC free article] [PubMed]
91. Epstein MD, Segal LN, Ibrahim SM, Friedman N, Bustami R. Snoring and the risk of obstructive sleep apnea in patients with pulmonary embolism. Sleep. 2010;33(8):1069–1074. [PubMed]
92. Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am. J. Respir. Crit. Care Med. 2004;169(3):348–353. [PubMed]
93. Toraldo DM, Peverini F, De Benedetto M, De Nuccio F. Obstructive sleep apnea syndrome: blood viscosity, blood coagulation abnormalities, and early atherosclerosis. Lung. 2013;191(1):1–7. [PubMed]
94. Alonso-Fernandez A, De La Pena M, Romero D, et al. Association between obstructive sleep apnea and pulmonary embolism. Mayo Clin. Proc. 2013;88(6):579–587. [PubMed]
95. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N. Engl. J. Med. 2005;353(19):2034–2041. [PubMed]
96. Arnardottir ES, Mackiewicz M, Gislason T, Teff KL, Pack AI. Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep. 2009;32(4):447–470. [PubMed]
97. Selim B, Won C, Yaggi HK. Cardiovascular consequences of sleep apnea. Clin. Chest Med. 2010;31(2):203–220. [PubMed]
98. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI–1) Circulation. 1989;79(1):101–106. [PubMed]
99. Zamarron C, Ricoy J, Riveiro A, Gude F. Plasminogen activator inhibitor–1 in obstructive sleep apnea patients with and without hypertension. Lung. 2008;186(3):151–156. [PubMed]
100. Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI–1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler. Thromb. 1993;13(10):1412–1417. [PubMed]
101. Eriksson BI, Eriksson E, Risberg B. Impaired fibrinolysis and postoperative thromboembolism in orthopedic patients. Thromb. Res. 1991;62(1–2):55–64. [PubMed]
102. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 2000;342(24):1792–1801. [PubMed]
103. Peng YH, Liao WC, Chung WS, et al. Association between obstructive sleep apnea and deep vein thrombosis/pulmonary embolism: a population-based retrospective cohort study. Thromb. Res. 2014;134(2):340–345. [PubMed]
104. Raiko JR, Oikonen M, Wendelin-Saarenhovi M, et al. Plasminogen activator inhitor–1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2012;224(1):208–212. [PubMed]
105. De Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013;309(21):2262–2269. [PubMed]
106. Bolden N, Smith CE, Auckley D, Makarski J, Avula R. Perioperative complications during use of an obstructive sleep apnea protocol following surgery and anesthesia. Anesth. Analg. 2007;105(6):1869–1870. [PubMed]
107. Chung F, Liao P, Elsaid H, Shapiro CM, Kang W. Factors associated with postoperative exacerbation of sleep-disordered breathing. Anesthesiology. 2014;120(2):299–311. [PubMed]
108. Chung SA, Yuan H, Chung F. A systemic review of obstructive sleep apnea and its implications for anesthesiologists. Anesth. Analg. 2008;107(5):1543–1563. [PubMed]
109. Gaddam S, Gunukula SK, Mador MJ. Post-operative outcomes in adult obstructive sleep apnea patients undergoing non-upper airway surgery: a systematic review and meta-analysis. Sleep Breath. 2013 Epub ahead of print. [PubMed]
110. Hwang D, Shakir N, Limann B, et al. Association of sleep-disordered breathing with postoperative complications. Chest. 2008;133(5):1128–1134. [PubMed]
111. Kaw R, Chung F, Pasupuleti V, Mehta J, Gay PC, Hernandez AV. Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. Br. J. Anaesth. 2012;109(6):897–906. [PubMed]
112. Kaw R, Mokhlesi B, Chung F, Gay P, Bolden N, Hillman D. Society of anesthesia and sleep medicine: proceedings of 2012 annual meeting. Sleep Breath. 2013;17(4):1333–1339. [PubMed]
113. Kaw R, Pasupuleti V, Walker E, Ramaswamy A, Foldvary-Schafer N. Postoperative complications in patients with obstructive sleep apnea. Chest. 2012;141(2):436–441. [PubMed]
114. Liao P, Yegneswaran B, Vairavanathan S, Zilberman P, Chung F. Postoperative complications in patients with obstructive sleep apnea: a retrospective matched cohort study. Can. J. Anaesth. 2009;56(11):819–828. [PubMed]
115. Memtsoudis SG, Stundner O, Rasul R, et al. Sleep apnea and total joint arthroplasty under various types of anesthesia: a population-based study of perioperative outcomes. Reg. Anesth. Pain Med. 2013;38(4):274–281. [PMC free article] [PubMed]
116. Mokhlesi B, Hovda MD, Vekhter B, Arora VM, Chung F, Meltzer DO. Sleep-disordered breathing and postoperative outcomes after bariatric surgery: analysis of the nationwide inpatient sample. Obes. Surg. 2013;23(11):1842–1851. [PMC free article] [PubMed]
117. Orlov D, Ankichetty S, Chung F, Brull R. Cardiorespiratory complications of neuraxial opioids in patients with obstructive sleep apnea: a systematic review. J. Clin. Anesth. 2013;25(7):591–599. [PubMed]
118. Svider PF, Pashkova AA, Folbe AJ, et al. Obstructive sleep apnea: strategies for minimizing liability and enhancing patient safety. Otolaryngol. Head Neck Surg. 2013;149(6):947–953. [PubMed]
119. Vasu TS, Grewal R, Doghramji K. Obstructive sleep apnea syndrome and perioperative complications: a systematic review of the literature. J. Clin. Sleep Med. 2012;8(2):199–207. [PubMed]
120. Austin L, Pulido L, Ropiak R, Porat M, Parvizi J, Rothman RH. Hypoxemia after total joint arthroplasty: a problem on the rise. J. Arthroplasty. 2008;23(7):1016–1021. [PubMed]
121. Basilico FC, Sweeney G, Losina E, et al. Risk factors for cardiovascular complications following total joint replacement surgery. Arthritis Rheum. 2008;58(7):1915–1920. [PMC free article] [PubMed]
122. Flink BJ, Rivelli SK, Cox EA, et al. Obstructive sleep apnea and incidence of postoperative delirium after elective knee replacement in the nondemented elderly. Anesthesiology. 2012;116(4):788–796. [PMC free article] [PubMed]
123. Guss D, Bhattacharyya T. Perioperative management of the obese orthopaedic patient. J. Am. Acad. Orthop. Surg. 2006;14(7):425–432. [PubMed]
124. Parvizi J, Huang R, Raphael IJ, Arnold WV, Rothman RH. Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors. Clin. Orthop. Relat. Res. 2014;472(3):903–912. [PMC free article] [PubMed]
125. Desborough JP. The stress response to trauma and surgery. Br. J. Anaesth. 2000;85(1):109–117. [PubMed]
126. American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep. A. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology. 2014;120(2):268–286. [PubMed]•• The American Society of Anesthesiology has published guidelines urging providers to screen for OSA preoperatively, refer high-risk patients to a sleep specialist for testing, diagnosis and treatment, and develop special considerations in the perioperative management of OSA patients.
127. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2011;57(19):e215–e367. [PubMed]
128. Agarwal SK, Avery CL, Ballantyne CM, et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin. Chem. 2011;57(6):891–897. [PMC free article] [PubMed]
129. Barbe F, Sanchez-De-La-Torre A, Abad J, et al. Effect of obstructive sleep apnoea on severity and short-term prognosis of acute coronary syndrome. Eur. Respir. J. 2015;45(2):419–427. [PubMed]
130. Barcelo A, Esquinas C, Bauca JM, et al. Effect of CPAP treatment on plasma high sensitivity troponin levels in patients with obstructive sleep apnea. Respir. Med. 2014;108(7):1060–1063. [PubMed]
131. Valo M, Wons A, Moeller A, Teupe C. Markers of myocardial ischemia in patients with obstructive sleep apnea and coronary artery disease. Pulm. Med. 2015;2015:621450. [PMC free article] [PubMed]
132. Hall TS, Herrscher T, Jarolim P, et al. Obstructive sleep apnea: no independent association to troponins. Sleep Breath. 2014;18(2):351–358. [PubMed]
133. Colish J, Walker JR, Elmayergi N, et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest. 2012;141(3):674–681. [PubMed]
134. Cifci N, Uyar M, Elbek O, Suyur H, Ekinci E. Impact of CPAP treatment on cardiac biomarkers and pro-BNP in obstructive sleep apnea syndrome. Sleep Breath. 2010;14(3):241–244. [PubMed]
135. Valo M, Wons A, Moeller A, Teupe C. Markers of myocardial ischemia in patients with coronary artery disease and obstructive sleep apnea: effect of continuous positive airway pressure therapy. Clin. Cardiol. 2015;38(8):462–468. [PubMed]
136. Maeder MT, Strobel W, Christ M, et al. Comprehensive biomarker profiling in patients with obstructive sleep apnea. Clin. Biochem. 2015;48(4–5):340–346. [PubMed]
137. Shah N, Redline S, Yaggi HK, et al. Obstructive sleep apnea and acute myocardial infarction severity: ischemic preconditioning? Sleep Breath. 2013;17(2):819–826. [PubMed]
138. Inami T, Seino Y, Otsuka T, et al. Links between sleep disordered breathing, coronary atherosclerotic burden, and cardiac biomarkers in patients with stable coronary artery disease. J. Cardiol. 2012;60(3):180–186. [PubMed]
139. Panagopoulou V, Deftereos S, Kossyvakis C, et al. NTproBNP: an important biomarker in cardiac diseases. Curr. Top. Med. Chem. 2013;13(2):82–94. [PubMed]
140. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293(13):1609–1616. [PubMed]
141. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108(3):275–281. [PubMed]
142. Biccard BM, Naidoo P. The role of brain natriuretic peptide in prognostication and reclassification of risk in patients undergoing vascular surgery. Anaesthesia. 2011;66(5):379–385. [PubMed]
143. Ryding AD, Kumar S, Worthington AM, Burgess D. Prognostic value of brain natriuretic peptide in noncardiac surgery: a meta-analysis. Anesthesiology. 2009;111(2):311–319. [PubMed]
144. Rodseth RN, Padayachee L, Biccard BM. A meta-analysis of the utility of pre-operative brain natriuretic peptide in predicting early and intermediate-term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia. 2008;63(11):1226–1233. [PubMed]
145. Rodseth RN, Lurati Buse GA, Bolliger D, et al. The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. J. Am. Coll. Cardiol. 2011;58(5):522–529. [PubMed]
146. Rodseth RN, Biccard BM, Chu R, et al. Postoperative B-type natriuretic peptide for prediction of major cardiac events in patients undergoing noncardiac surgery: systematic review and individual patient meta-analysis. Anesthesiology. 2013;119(2):270–283. [PubMed]
147. Rodseth RN, Biccard BM, Le Manach Y, et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J. Am. Coll. Cardiol. 2014;63(2):170–180. [PubMed]
148. Montagnana M, Lippi G, Regis D, et al. Evaluation of cardiac involvement following major orthopedic surgery. Clin. Chem. Lab. Med. 2006;44(11):1340–1346. [PubMed]
149. Hubner RH, El Mokhtari NE, Freitag S, et al. NT-proBNP is not elevated in patients with obstructive sleep apnoea. Respir. Med. 2008;102(1):134–142. [PubMed]
150. Maeder MT, Ammann P, Rickli H, et al. N-terminal pro-B-type natriuretic peptide and functional capacity in patients with obstructive sleep apnea. Sleep Breath. 2008;12(1):7–16. [PubMed]
151. Patwardhan AA, Larson MG, Levy D, et al. Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample. Sleep. 2006;29(10):1301–1306. [PubMed]

Articles from Biomarkers in Medicine are provided here courtesy of Future Science Group